Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been dominated by chemotherapy; however, the approval of Celgene’s Vidaza (azacitidine) in 2017 and the expected approvals in China between 2020 and 2023 of several therapies available in Western markets will transform the AML treatment landscape. The entry of novel agents into the treatment paradigm will enable increasingly personalized treatment. However, several areas of unmet need remain. Notably, significant commercial opportunity existsfor innovative agents to treat patients unfit for intensive chemotherapy induction and relapsed/refractory AML patients. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are more likely to be encouraged to enter this market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Qualitative and quantitative insights from five thought-leading hematologist-oncologists in China, supported by survey data collected for this and other DRG research.
Diagnosed prevalence of AML in urban versus rural China; clinically relevant and market-relevant drug-treatable populations .
10-year, annualized, drug-level sales and patient shares of key AML regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 8 drugs; Phase II: 5 drugs; coverage of select preclinical and Phase I products.